Tenderwize
Zurück zur Suche

Open House Discount Agreement Erythropoietin alfa

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 309 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin alfa, ATC B03XA01

60/100

Opportunity Score

PromisingLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

60 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated value or volume commitment; actual business may be minimal.

Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Strong opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive discount agreement for Erythropoietin alfa (ATC B03XA01) with AOK Bayern
  • Supply of pharmaceutical products containing the active substance Erythropoietin alfa
Vollständige Zusammenfassung anzeigen

Open house non-exclusive discount agreement for the pharmaceutical product Erythropoietin alfa (ATC B03XA01) with AOK Bayern. All interested pharmaceutical companies meeting eligibility criteria can conclude identical, non-negotiable discount agreements. Contracts run from 1 September 2025 to 31 August 2027, with possible termination. This is not a classic procurement procedure but a non-exclusive open-house model under §130a SGB V. No estimated value is published.

Risiken

No estimated value or volume commitment; actual business may be minimal.

Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible to participate

Administrative

  • Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Submission of the signed contract including the completed appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

No award criteria; open house model with equal terms for all.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Discount Agreement Erythropoietin alfa

Single lot covering the active substance Erythropoietin alfa. All interested pharmaceutical companies that meet the eligibility criteria can conclude the same discount agreement. The contract can be concluded at any time during the term, latest by 3 July 2027. Submission must be via the communication area of the dtvp portal (not the offer area) or by post with specific deadlines.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Aug 2025 - Aug 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria; open house model with equal terms for all.

Frist

Deadline Jul 03, 2027

Vergabedetails

Veröffentlichungsdatum
13 Jul 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
458024-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30